GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anavex Life Sciences Corp (NAS:AVXL) » Definitions » Degree of Financial Leverage

Anavex Life Sciences (Anavex Life Sciences) Degree of Financial Leverage : 1.30 (As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Anavex Life Sciences Degree of Financial Leverage?

Degree of Financial Leverage (DFL) measures the percentage change in EPS for a unit change in Earnings Before Interest and Taxes (EBIT). Anavex Life Sciences's Degree of Financial Leverage for the quarter that ended in Dec. 2023 was 1.30. The higher Degree of Financial Leverage, the more volatile earnings will be.

The industry rank for Anavex Life Sciences's Degree of Financial Leverage or its related term are showing as below:

AVXL's Degree of Financial Leverage is ranked worse than
73.52% of 1488 companies
in the Biotechnology industry
Industry Median: 0.97 vs AVXL: 1.30

Anavex Life Sciences Degree of Financial Leverage Historical Data

The historical data trend for Anavex Life Sciences's Degree of Financial Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anavex Life Sciences Degree of Financial Leverage Chart

Anavex Life Sciences Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Degree of Financial Leverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.77 -2.25 0.82 0.53 -0.57

Anavex Life Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Degree of Financial Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.55 0.61 0.45 -0.57 1.30

Competitive Comparison of Anavex Life Sciences's Degree of Financial Leverage

For the Biotechnology subindustry, Anavex Life Sciences's Degree of Financial Leverage, along with its competitors' market caps and Degree of Financial Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anavex Life Sciences's Degree of Financial Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anavex Life Sciences's Degree of Financial Leverage distribution charts can be found below:

* The bar in red indicates where Anavex Life Sciences's Degree of Financial Leverage falls into.



Anavex Life Sciences Degree of Financial Leverage Calculation

Anavex Life Sciences's Degree of Financial Leverage for the quarter that ended in Dec. 2023 is calculated as:

Degree of Financial Leverage=% Change in Earnings per Share (Diluted)**/% Change in EBIT
=( -0.55 (Dec. 2023) / -0.65 (Dec. 2022) - 1 )/( -46.931 (Dec. 2023) / -53.239 (Dec. 2022) - 1 )
=-0.1538/-0.1185
=1.30***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EPS and EBIT was used to calculate Degree of Financial Leverage.
*** Please be aware that the Degree of Financial Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Anavex Life Sciences  (NAS:AVXL) Degree of Financial Leverage Explanation

Degree of Financial Leverage (DFL) is a leverage ratio that measures the sensitivity of a company’s Earnings per Share (EPS) to fluctuations in its operating income, also referred to as Earnings Before Interest and Taxes (EBIT), resulting from adjustments in its capital structure. DFL is an essential tool for companies to assess the appropriate level of debt or financial leverage in their capital structure. When EBIT remains relatively stable, it results in stable earnings and earnings per share. In such cases, the company may consider taking on substantial debt. However, for companies operating in industries with significant fluctuations in EBIT, it is advisable to keep debt at a manageable level.

The higher Degree of Financial Leverage, the more volatile earnings will be. Because interest is a fixed expense, leverage can amplify earnings and EPS. This is beneficial when EBIT is growing, but it can become problematic in tough economic conditions when EBIT is under pressure.

Be Aware

The use of financial leverage varies across different industries and business sectors, and the application of Degree of Financial Leverage (DFL) should be adjusted accordingly.


Anavex Life Sciences Degree of Financial Leverage Related Terms

Thank you for viewing the detailed overview of Anavex Life Sciences's Degree of Financial Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Anavex Life Sciences (Anavex Life Sciences) Business Description

Traded in Other Exchanges
Address
630 5th Avenue, 20th Floor, New York, NY, USA, 10111
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.
Executives
Christopher U Missling director, officer: President, CEO, CFO, Treasurer, other: Secretary 61 MOULTON ST, CAMBRIDGE MA 02138
Athanasios Skarpelos 10 percent owner 14,RUE KLEBERG, GENEVA V8 CH-1201
Jiong Ma director 445 PARK AVENUE, 9TH FLOOR, NEW YORK NY 10022
Elliot Favus director 51 W 52ND STREET, 7TH FLOOR, NEW YORK NY 10091
Donhauser Peter D.o. director REGINA-KIRCHMAIER STRASSE 4, KAUFBEUREN 2M 87600
Sandra Boenisch officer: PFO & Treasurer 51 WEST 52ND STREET, 7TH FLOOR, NEW YORK NY 10019
Claus Vander Velden director PO BOX MUENSTEREIFELER ST., COLOGNE 2M 50937
Steffen Thomas director FALLMERAYER STR. 19, MUNICH 2M 80796
Bernd Metzner director 51 W 52ND STREET, 7TH FLOOR, NEW YORK NY 10019
George F Tidmarsh director, officer: Executive Director
John Robert Chisholm director 16308 36A AVENUE, SURREY A1 V3S 0X5
William Sean Lowry director 1172 BAY STREET, SUITE 300, ONTARIO Z4 M5S1L9
David L. Tousley director 14610 PAWNEE LANE, LEAWOOD KS 66224
Harvey Lalach director, officer: President CEO CFO 4837 CANYON RIDGE CRESENT, KELOWNA A1 V1W 4A1
Alison E. Ayers director 27 O'CONNOR CIRCLE, WEST ORANGE NJ 07052